Health Canada Approves Evrysdi for At-home Treatment

Health Canada Approves Evrysdi for At-home Treatment

292029

Health Canada Approves Evrysdi for At-home Treatment

Evrysdi (risdiplam) has been approved by Health Canada for the at-home treatment of spinal muscular atrophy (SMA) in people ages 2 months and older. “The Health Canada approval of Evrysdi is a welcome addition in our ability to treat SMA. It is an efficacious treatment that significantly increases survival motor neuron (SMN) protein in SMA patients,” Hugh McMillan, MD, a pediatric neurologist at the Children’s Hospital of Eastern Ontario, said in a press release. “We…

You must be logged in to read/download the full post.